(2E)-N-ethenylpenta-2,4-dien-2-amine

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: (2E)-N-ethenylpenta-2,4-dien-2-amine
• 化学式: C₇H₁₁N
• 分子量: 109.17
• InChiKey: BZSMBXOEDUDZMX-VOTSOKGWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  8
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

文献信息

• [EN] IMPROVED PROCESS FOR PREPARING BENZOFURAN-2-CARBOXAMIDE DERIVATIVES<br/>[FR] PROCÉDÉ AMÉLIORÉ DE PRÉPARATION DE DÉRIVÉS DE BENZOFURAN-2-CARBOXAMIDE
  申请人：SYMED LABS LTD

  公开号：WO2014006637A2

  公开（公告）日：2014-01-09

  Provided herein are novel, commercially viable and industrially advantageous processes for the preparation of benzofuran-2-carboxamide derivatives and their intermediates, or a pharmaceutically acceptable salt thereof, in high yield and purity. Provided particularly herein are novel, commercially viable and industrially advantageous processes for the preparation of vilazodone or a pharmaceutically acceptable salt thereof in high yield and purity. Provided also herein is an improved and commercially viable process for the preparation of 3-(4-hydroxybutyl)-1H-indole-5-carbonitrile, in high yield and purity, using novel intermediate compound 3-(4-hydroxybutyryl)-1H-indole-5-carbonitrile.

  本文提供了一种新颖、商业可行和工业优越的过程，用于制备苯并呋喃-2-羧酰胺衍生物及其中间体或其药学上可接受的盐，收率和纯度高。特别提供了一种新颖、商业可行和工业优越的过程，用于制备维拉唑酮或其药学上可接受的盐，收率和纯度高。本文还提供了一种改进的、商业可行的过程，用于使用新颖的中间体化合物3-(4-羟基丁酰基)-1H-吲哚-5-碳腈，高收率和高纯度地制备3-(4-羟基丁基)-1H-吲哚-5-碳腈。
• AUXIN-INDUCIBLE DEGRON SYSTEM KIT AND USE THEREOF
  申请人：Inter-University Research Institute Corporation Research Organization of Information and Systems

  公开号：EP4026828A1

  公开（公告）日：2022-07-13

  An auxin-inducible degron system kit that controls degradation of a target protein in a non-plant-derived eukaryotic cell, the kit containing a first nucleic acid that encodes a mutant TIR1 family protein having a mutation at an auxin-binding site, an auxin analog that has an affinity to the mutant TIR1 family protein and a second nucleic acid that encodes a degradation tag containing at least a part of an Aux/IAA family protein and having an affinity to a complex of the mutant TIR1 family protein and the auxin analog.

  一种可控制非植物源真核细胞中目标蛋白质降解的辅助素诱导降解子系统试剂盒，该试剂盒包含第一种核酸，该核酸编码在辅助素结合位点发生突变的突变体 TIR1 家族蛋白、与突变型 TIR1 家族蛋白具有亲和力的辅助素类似物，以及编码降解标签的第二核酸，该降解标签至少含有部分 Aux/IAA 家族蛋白，并与突变型 TIR1 家族蛋白和辅助素类似物的复合物具有亲和力。
• Compounds for the treatment of HIV
  申请人：Gilead Sciences, Inc.

  公开号：US10370358B2

  公开（公告）日：2019-08-06

  The invention provides compounds of formula (I): or a salt thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of formula (I), processes for preparing compounds of formula (I), intermediates useful for preparing compounds of formula I and therapeutic methods for treating a Retroviridae viral infection including an infection caused by the HIV virus.

  本发明提供如本文所述的式(I)化合物或其盐。本发明还提供了包含式（I）化合物的药物组合物、制备式（I）化合物的工艺、用于制备式（I）化合物的中间体以及治疗逆转录病毒科病毒感染（包括由 HIV 病毒引起的感染）的治疗方法。
• N-{[2-(piperidin-1-yl)phenyl](phenyl)methyl}-2-(3-oxo-3,4-dihydro-2H-1,4-benzoxazin-7-yl)acetamide derivatives and related compounds as ROR-gamma modulators for treating autoimmune diseases
  申请人：Genfit

  公开号：US11052092B2

  公开（公告）日：2021-07-06

  The present invention provides e.g. N-[2-(piperidin-1-yl)phenyl](phenyl)methyl}-2-(3-oxo-3,4-dihydro-2H-1,4-benzoxazin-7-yl)acetamide derivatives and related compounds as ROR-gamma modulators for treating e.g. autoimmune diseases, autoimmune-related diseases, inflammatory diseases, metabolic diseases, fibrotic diseases or cholestatic diseases, such as e.g. arthitis and asthma.

  本发明提供了例如N-[2-(哌啶-1-基)苯基](苯基)甲基}-2-(3-氧代-3,4-二氢-2H-1,4-苯并恶嗪-7-基)乙酰胺衍生物和相关化合物作为ROR-γ调节剂，用于治疗例如自身免疫性疾病、自身免疫相关疾病、炎症性疾病、代谢性疾病、纤维化疾病或胆汁淤积性疾病，例如关节炎和哮喘。
• Compounds For the Treatment of HIV
  申请人：Gilead Sciences, Inc.

  公开号：US20180194746A1

  公开（公告）日：2018-07-12

  The invention provides compounds of formula (I): or a salt thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of formula (I), processes for preparing compounds of formula (I), intermediates useful for preparing compounds of formula I and therapeutic methods for treating a Retroviridae viral infection including an infection caused by the HIV virus.